A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1

Sadanori Abe, Masao Kojima, Hiroaki Kurihara, Hikaru Tamura, Minoru Kitago, Hideyuki Sasanuma, Masahiro Wada, Tomonobu Ogihara

Research output: Contribution to journalArticle

Abstract

The patient was a 64-year-old male. On November 21, 1991, he underwent gastric resection on the pyloric side for early gastric cancer in the authors' hospital, and did not experience recurrence for many years thereafter. However, endoscopic examination of the upper gastrointestinal tract performed on June 11, 1999 revealed advanced cancer in the posterior wall of the residual stomach which was accompanied by invasion of the esophagus. Thus, the residual stomach was completely removed on July 5, 1999. The histopathological findings were tub1, se, ly3, v2, aw(-), ow(+) and ew(+), and a portion of the esophageal stump and the serosa of the lesser curvature were positive for cancerous tissue. Endoscopic examination was performed one month after the operation, on August 7, 1999. A forceps biopsy taken from an elevated lesion of the esophagus at the posterior wall of the anastomosis revealed adenocarcinoma cells in the lower layer of the squamous epithelium. A residual esophageal lesion was thus diagnosed. Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i.e., 50 mg/day). After completion of one course of this therapy, endoscopy was again performed. It was found that the prominence on the esophageal mucosa at the anastomosis, which had been diagnosed as being cancerous tissue, had shrunk in size, while a forceps biopsy taken from the same site yielded no findings of malignancy. The patient was followed for 18 months thereafter, and endoscopy was performed three times during that interval but continued to yield no evidence of malignancy. As of February 2001, this patient had completed 12 courses of TS-1 at one-half its usual dosage. There have been no findings of recurrence, and the patient's course continues to be good. In summary, this was an interesting case in which residual cancer was detected in the esophageal stump following resection for gastric cancer, and it can be concluded that TS-1 therapy was effective in spite of being incomplete (i.e., half-dose), eradicating the residual cancer tissue.

Original languageEnglish
Pages (from-to)1421-1426
Number of pages6
JournalJapanese Journal of Cancer and Chemotherapy
Volume29
Issue number8
Publication statusPublished - 2002 Aug
Externally publishedYes

Fingerprint

Gastric Stump
Residual Neoplasm
Stomach Neoplasms
Surgical Instruments
Esophagus
Endoscopy
Biopsy
Recurrence
Serous Membrane
Neoplasms
Upper Gastrointestinal Tract
Stomach
Adenocarcinoma
Epithelium
titanium silicide
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1. / Abe, Sadanori; Kojima, Masao; Kurihara, Hiroaki; Tamura, Hikaru; Kitago, Minoru; Sasanuma, Hideyuki; Wada, Masahiro; Ogihara, Tomonobu.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 29, No. 8, 08.2002, p. 1421-1426.

Research output: Contribution to journalArticle

Abe, Sadanori ; Kojima, Masao ; Kurihara, Hiroaki ; Tamura, Hikaru ; Kitago, Minoru ; Sasanuma, Hideyuki ; Wada, Masahiro ; Ogihara, Tomonobu. / A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1. In: Japanese Journal of Cancer and Chemotherapy. 2002 ; Vol. 29, No. 8. pp. 1421-1426.
@article{dc9a6677f8ca4bc587c0aadc65d97b4a,
title = "A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1",
abstract = "The patient was a 64-year-old male. On November 21, 1991, he underwent gastric resection on the pyloric side for early gastric cancer in the authors' hospital, and did not experience recurrence for many years thereafter. However, endoscopic examination of the upper gastrointestinal tract performed on June 11, 1999 revealed advanced cancer in the posterior wall of the residual stomach which was accompanied by invasion of the esophagus. Thus, the residual stomach was completely removed on July 5, 1999. The histopathological findings were tub1, se, ly3, v2, aw(-), ow(+) and ew(+), and a portion of the esophageal stump and the serosa of the lesser curvature were positive for cancerous tissue. Endoscopic examination was performed one month after the operation, on August 7, 1999. A forceps biopsy taken from an elevated lesion of the esophagus at the posterior wall of the anastomosis revealed adenocarcinoma cells in the lower layer of the squamous epithelium. A residual esophageal lesion was thus diagnosed. Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i.e., 50 mg/day). After completion of one course of this therapy, endoscopy was again performed. It was found that the prominence on the esophageal mucosa at the anastomosis, which had been diagnosed as being cancerous tissue, had shrunk in size, while a forceps biopsy taken from the same site yielded no findings of malignancy. The patient was followed for 18 months thereafter, and endoscopy was performed three times during that interval but continued to yield no evidence of malignancy. As of February 2001, this patient had completed 12 courses of TS-1 at one-half its usual dosage. There have been no findings of recurrence, and the patient's course continues to be good. In summary, this was an interesting case in which residual cancer was detected in the esophageal stump following resection for gastric cancer, and it can be concluded that TS-1 therapy was effective in spite of being incomplete (i.e., half-dose), eradicating the residual cancer tissue.",
author = "Sadanori Abe and Masao Kojima and Hiroaki Kurihara and Hikaru Tamura and Minoru Kitago and Hideyuki Sasanuma and Masahiro Wada and Tomonobu Ogihara",
year = "2002",
month = "8",
language = "English",
volume = "29",
pages = "1421--1426",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",

}

TY - JOUR

T1 - A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1

AU - Abe, Sadanori

AU - Kojima, Masao

AU - Kurihara, Hiroaki

AU - Tamura, Hikaru

AU - Kitago, Minoru

AU - Sasanuma, Hideyuki

AU - Wada, Masahiro

AU - Ogihara, Tomonobu

PY - 2002/8

Y1 - 2002/8

N2 - The patient was a 64-year-old male. On November 21, 1991, he underwent gastric resection on the pyloric side for early gastric cancer in the authors' hospital, and did not experience recurrence for many years thereafter. However, endoscopic examination of the upper gastrointestinal tract performed on June 11, 1999 revealed advanced cancer in the posterior wall of the residual stomach which was accompanied by invasion of the esophagus. Thus, the residual stomach was completely removed on July 5, 1999. The histopathological findings were tub1, se, ly3, v2, aw(-), ow(+) and ew(+), and a portion of the esophageal stump and the serosa of the lesser curvature were positive for cancerous tissue. Endoscopic examination was performed one month after the operation, on August 7, 1999. A forceps biopsy taken from an elevated lesion of the esophagus at the posterior wall of the anastomosis revealed adenocarcinoma cells in the lower layer of the squamous epithelium. A residual esophageal lesion was thus diagnosed. Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i.e., 50 mg/day). After completion of one course of this therapy, endoscopy was again performed. It was found that the prominence on the esophageal mucosa at the anastomosis, which had been diagnosed as being cancerous tissue, had shrunk in size, while a forceps biopsy taken from the same site yielded no findings of malignancy. The patient was followed for 18 months thereafter, and endoscopy was performed three times during that interval but continued to yield no evidence of malignancy. As of February 2001, this patient had completed 12 courses of TS-1 at one-half its usual dosage. There have been no findings of recurrence, and the patient's course continues to be good. In summary, this was an interesting case in which residual cancer was detected in the esophageal stump following resection for gastric cancer, and it can be concluded that TS-1 therapy was effective in spite of being incomplete (i.e., half-dose), eradicating the residual cancer tissue.

AB - The patient was a 64-year-old male. On November 21, 1991, he underwent gastric resection on the pyloric side for early gastric cancer in the authors' hospital, and did not experience recurrence for many years thereafter. However, endoscopic examination of the upper gastrointestinal tract performed on June 11, 1999 revealed advanced cancer in the posterior wall of the residual stomach which was accompanied by invasion of the esophagus. Thus, the residual stomach was completely removed on July 5, 1999. The histopathological findings were tub1, se, ly3, v2, aw(-), ow(+) and ew(+), and a portion of the esophageal stump and the serosa of the lesser curvature were positive for cancerous tissue. Endoscopic examination was performed one month after the operation, on August 7, 1999. A forceps biopsy taken from an elevated lesion of the esophagus at the posterior wall of the anastomosis revealed adenocarcinoma cells in the lower layer of the squamous epithelium. A residual esophageal lesion was thus diagnosed. Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i.e., 50 mg/day). After completion of one course of this therapy, endoscopy was again performed. It was found that the prominence on the esophageal mucosa at the anastomosis, which had been diagnosed as being cancerous tissue, had shrunk in size, while a forceps biopsy taken from the same site yielded no findings of malignancy. The patient was followed for 18 months thereafter, and endoscopy was performed three times during that interval but continued to yield no evidence of malignancy. As of February 2001, this patient had completed 12 courses of TS-1 at one-half its usual dosage. There have been no findings of recurrence, and the patient's course continues to be good. In summary, this was an interesting case in which residual cancer was detected in the esophageal stump following resection for gastric cancer, and it can be concluded that TS-1 therapy was effective in spite of being incomplete (i.e., half-dose), eradicating the residual cancer tissue.

UR - http://www.scopus.com/inward/record.url?scp=0036690811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036690811&partnerID=8YFLogxK

M3 - Article

C2 - 12214471

AN - SCOPUS:0036690811

VL - 29

SP - 1421

EP - 1426

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 8

ER -